Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations

Martin Zenker1, Katarina Lehmann, Anna Leana Schulz

  • 1Institute of Human Genetics, University of Erlangen-Nuremberg, Germany.

Abstract

Insights

Germline KRAS mutations are linked to Noonan, cardio-facio-cutaneous (CFC), and Costello syndromes. These mutations cause a wide range of clinical features, highlighting K-Ras

Area of Science:

  • Genetics
  • Molecular Biology
  • Developmental Biology

Background:

  • Noonan, cardio-facio-cutaneous (CFC), and Costello syndromes share overlapping congenital anomalies.
  • These disorders are linked to mutations in the Ras-MAPK pathway.
  • Germline KRAS mutations have been identified in some Noonan and CFC patients.

Purpose of the Study:

  • Investigate KRAS mutations in patients with Noonan, CFC, and Costello syndromes.
  • Define the phenotypic spectrum associated with KRAS mutations.
  • Compare clinical differences between KRAS mutation carriers and patients with mutations in other Ras-MAPK pathway genes.

Main Methods:

  • Screened 260 patients for KRAS mutations using direct sequencing.
  • Analyzed detected KRAS mutations for predicted amino acid substitutions.
  • Correlated genotypes with clinical phenotypes.

Main Results:

  • Detected KRAS mutations in 12 out of 260 patients (3 known, 8 novel alterations).
  • Observed significant clinical variability, including features of Noonan, CFC, and Costello syndromes.
  • Identified two patients meeting Costello syndrome criteria with KRAS mutations.

Conclusions:

  • KRAS germline alterations are associated with a spectrum of related developmental disorders.
  • KRAS mutations contribute to phenotypic variability, potentially influenced by specific genotypes.
  • K-Ras plays a central role in multiple signaling pathways, explaining the observed clinical diversity.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...